ClinicalTrials.gg
CompletedNCT00392080Updated Mar 24, 2008

A Study Of The Effect Of CJ-023,423 On The Incidence Of Stomach Ulcers

A Phase 1 interventional study of CJ-023,423 and placebo in Osteoarthritis, sponsored by Pfizer. Completed at 11 sites in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2008-03-24.

Sponsored by Pfizer · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
340
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 14 studies testing naproxen in Osteoarthritis — none open to participants now, 1 under way, none of them phase 3. Naproxen · Osteoarthritis.

Planned enrollment
3rd of 14
340 · median 103
Started
2006
with 1 other
Phase 1
5 of 14
none open now
Registered
3rd of 14
by date
Lead sponsor
6 of 14
Pfizer

Among the 14 studies testing naproxen in Osteoarthritis, this one is the 3rd largest by planned enrollment, is one of 2 that started in 2006, is one of 5 in phase 1, and was the 3rd registered.

Osteoarthritis

2,978 studies on the registry are indexed under Osteoarthritis; 437 are open to participants now.

Browse Osteoarthritis studies →

Open to participants now

None of the 14 studies testing naproxen in Osteoarthritis is open now. The open studies under Osteoarthritis, anywhere →

About naproxen

Naproxen: first FDA approval 1976 (NAPROSYN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 285 Osteoarthritis studies recruiting now, 158 (55%) set no upper age limit and 70 (25%) stop at 75 or younger; 22 take children under 18; 31 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 14 studies testing naproxen in Osteoarthritis as a file.
02

Study summary

CJ-023,423 is a new medication being developed as an anti-inflammatory agent for the treatment of the signs and symptoms of osteoarthritis (OA). The purpose of this study is to evaluate whether patients treated with CJ-023,423 for 7 days (14 doses) have fewer gastrointestinal ulcers compared to patients treated with naproxen and placebo.

03

Conditions studied

  • Osteoarthritis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Is a healthy adult 18 to 75 years of age, inclusive; healthy is defined as no abnormalities identified as detailed medical history, full physical examination, including blood pressure [BP] and pulse rate [PR]measurement, 12-lead [ECG], and clinical safety laboratory tests
  • If female and of (includes women who have been for \< 2 years ), must be using adequate , must not be lactating and must have had a negative serum pregnancy test at Screening and a negative urine pregnancy test result within 24 hours prior to receiving study drug. The site investigator must ensure that female subjects are not pregnant prior to receiving the first dose of drug;

Exclusion criteria

Exclusion Criteria:

  • Endoscopic evidence of inflammation, ulceration, erosion, petechiae, or active bleeding in the esophagus, stomach, pyloric channel, or duodenum at the baseline/ randomization (Day 1) endoscopy (Mucosal Grading Scale score >0);
  • Active GI disease (e.g. inflammatory bowel disease), a history of gastroduodenal ulcers or bleeding, or a history of any gastric or duodenal surgery;
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
340 participants (estimated)

Study arms

  • Placebo comparator
    3

    Drug: placebo

  • Experimental
    1

    75 mg BID

    Drug: naproxen

  • Experimental
    2

    Drug: CJ-023,423

Interventions

06

What researchers measure

Primary outcomes

  1. The primary endpoint is the presence of gastroduodenal ulcers in each subject, as determined by a UGI endoscopy at the end of the treatment

    Time frame: 7 days

Secondary outcomes

  1. Incidence of treatment-emergent, all-causality GI body system adverse events

    Time frame: Duration of trial

  2. Severity of Dyspepsia Assessment (SODA)

    Time frame: Duration of trial

  3. Post treatment gastric, duodenal and gastroduodenal endoscopic scores (according to the mucosal grading scale). The gastroduodenal score is defined as the higher of the gastric and duodenal scores.

    Time frame: Duration of trial

  4. Incidence of any gastric ulcer

    Time frame: Duration of trial

  5. Incidence of any duodenal ulcer

    Time frame: Duration of trial

  6. Incidence of any gastroduodenal erosion or ulcer

    Time frame: Duration of trial

  7. Incidence of any gastric erosion or ulcer

    Time frame: Duration of trial

  8. Incidence of any duodenal erosion or ulcer

    Time frame: Duration of trial

  9. Incidence of any esophageal ulcer using the traditional grading method of: normal, erosion or ulcer

    Time frame: Duration of trial

  10. Incidence of any esophageal ulcer or erosion using the LA classification: esophageal ulcers and erosions method with a Grade A, B, C, or D)

    Time frame: Duration of trial

  11. Number of gastroduodenal ulcers in each subject

    Time frame: Duration of trial

07

Study locations

11 sites
  • Pfizer Investigational Site
    Anaheim, California 92801, United States
  • Pfizer Investigational Site
    San Diego, California 92103-6204, United States
  • Pfizer Investigational Site
    Jupiter, Florida 33458, United States
  • Pfizer Investigational Site
    Ocoee, Florida 34761, United States
  • Pfizer Investigational Site
    South Miami, Florida 33143, United States
  • Pfizer Investigational Site
    New York, New York 10021, United States
  • Pfizer Investigational Site
    Raleigh, North Carolina 27607, United States
  • Pfizer Investigational Site
    Raleigh, North Carolina 27612, United States
  • Pfizer Investigational Site
    Houston, Texas 77074, United States
  • Pfizer Investigational Site
    Houston, Texas 77090, United States
  • Pfizer Investigational Site
    Chesapeake, Virginia 23320, United States
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2006 and a completion of Feb 2008. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 23, 2006
First posted
Oct 25, 2006
Start
Nov 2006
CompletionActual
Feb 2008
Last update
Mar 24, 2008
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 24, 2008, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00392080
Lead sponsor
Pfizer
First posted
Oct 25, 2006
Start date
Nov 2006
Completion
Feb 2008
Last update
Mar 24, 2008

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2008. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Grapiprant · Naproxen

Start the discussion